Active, not recruitingNCT06553638

Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Hospital, Brest
Enrollment
50 target
Eligibility
18 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06553638 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm

← Back to all trials